BMB18 clinical trial expands to dual site
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Recruitment for the trial is starting this week, aligning with previously disclosed timelines. The trial has expanded from a single site to include Harokopio University of Athens, enhancing its credibility and recruitment potential.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Biome Australia's latest callBiome Australia (ASX:BIO) Q1 2026 Earnings Call · Replay · Oct 22, 2025Read the transcript of Biome Australia (ASX:BIO) Q1 2026 Earnings CallEarlier from Biome Australia
- Probiotical Exclusive Supply Agreement Extended
- Patent Application Filed for Probiotic Strain BMB18
- Biome First Half FY26 Results and Highlights
- Appendix 4D & Half Yearly Report
- Ethics Approval Granted for BMB18 Human Clinical Trial
Later from Biome Australia
- Biome Signs Australian Manufacturing Agreement
- FY26 Trading Update
- International Markets Presentation
- Quarterly Activities & Cashflow Report
- Preliminary Final Report
Follow Biome Australia into a list and get an email when it puts out news.
Follow Biome Australia